卵巢癌肠转移相关基因的鉴定与临床关联研究
本研究对高级别浆液性卵巢癌原发肿瘤及其配对肠转移灶进行RNA测序(发现集21例、重复集18例),在重复集中确认21个差异表达基因;在333例独立队列中,过半基因在原发肿瘤中高表达与初次手术需肠切除及无法达到完全细胞减灭相关;LRRC15敲低可显著抑制小鼠肿瘤进展。
要点
- 发现集27个差异表达基因中21个在重复集确认,包括SFRP2、Col11A1、LRRC15等。
- 原发肿瘤中过半上述基因高表达与初次手术需肠切除及无法完全细胞减灭相关。
- LRRC15在肠转移灶中高表达经免疫组化确认,敲低可显著抑制小鼠肿瘤进展。
核心结论
- 研究鉴定出21个在卵巢癌肠转移灶中过表达的基因,有助于筛选预防和治疗卵巢癌恶性肠梗阻的潜在分子靶点。
研究设计与样本
- 对高级别浆液性卵巢癌原发肿瘤及配对肠转移灶行RNA测序,发现集21例、重复集18例,差异表达基因经定量逆转录PCR验证。
- 使用333例独立卵巢癌队列分析原发肿瘤差异表达基因与手术及临床结局的关联。
- 行免疫组化和小鼠异种移植研究确认LRRC15促进转移的作用。
主要发现
- 发现集27个差异表达基因中21个在重复集确认:SFRP2、Col11A1、LRRC15、ADAM12、ADAMTS12、MFAP5、LUM、PLPP4、FAP、POSTN、GRP、MMP11、MMP13、C1QTNF3、EPYC、DIO2、KCNA1、NETO1、NTM、MYH13和PVALB。
- 原发肿瘤中过半上述基因高表达与初次手术需肠切除增加及无法达到完全细胞减灭相关。
- LRRC15在肠转移灶中高表达经免疫组化确认,敲低LRRC15可显著抑制小鼠肿瘤进展。
关键数值与推荐
- 差异表达基因定义为在至少30%患者中肠转移灶表达较原发肿瘤高至少2倍(P<.05),且配对良性肠组织无表达升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study is designed to identify genes and pathways that could promote metastasis to the bowel in high-grade serous ovarian cancer (OC) and evaluate their associations with clinical outcomes. METHODS: We performed RNA sequencing of OC primary tumors (PTs) and their corresponding bowel metastases (n = 21 discovery set; n = 18 replication set). Differentially expressed genes (DEGs) were those expressed at least 2-fold higher in bowel metastases (BMets) than PTs in at least 30% of patients (P < .05) with no increased expression in paired benign bowel tissue and were validated with quantitative reverse transcription PCR. Using an independent OC cohort (n = 333), associations between DEGs in PTs and surgical and clinical outcomes were performed. Immunohistochemistry and mouse xenograft studies were performed to confirm the role of LRRC15 in promoting metastasis. RESULTS: Among 27 DEGs in the discovery set, 21 were confirmed in the replication set: SFRP2, Col11A1, LRRC15, ADAM12, ADAMTS12, MFAP5, LUM, PLPP4, FAP, POSTN, GRP, MMP11, MMP13, C1QTNF3, EPYC, DIO2, KCNA1, NETO1, NTM, MYH13, and PVALB. Higher expression of more than half of the genes in the PT was associated with an increased requirement for bowel resection at primary surgery and an inability to achieve complete cytoreduction. Increased expression of LRRC15 in BMets was confirmed by immunohistochemistry and knockdown of LRRC15 significantly inhibited tumor progression in mice. CONCLUSIONS: We identified 21 genes that are overexpressed in bowel metastases among patients with OC. Our findings will help select potential molecular targets for the prevention and treatment of malignant bowel obstruction in OC.
引用
- Mariani A, Wang C, Oberg AL, et al. Genes associated with bowel metastases in ovarian cancer. Gynecol Oncol. 2019. PMID: 31204077. doi:10.1016/j.ygyno.2019.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。